diarrhoea
caus
cryptosporidium
parvum
major
problem
calv
younger
week
age
date
compound
approv
prophylact
none
therapeut
use
nitazoxanid
ntz
proven
efficaci
vitro
c
parvum
approv
fda
treatment
human
cryptosporidiosi
first
experiment
studi
uninfect
calv
treat
ntz
pharmacokinet
follow
blood
sampl
serum
sampl
uninfect
treat
calv
contain
ntz
metabolit
tizoxanid
tizoxanid
glucuronid
oral
administr
h
interv
consid
optim
three
group
three
calv
day
old
inocul
oocyst
c
parvum
cattl
genotyp
prophylact
group
receiv
mgkg
bodi
weight
ntz
twice
daili
oral
milk
day
day
postinocul
dpi
therapeut
group
receiv
dosag
ntz
day
appear
diarrhoea
dpi
control
group
left
untreat
calv
monitor
daili
day
dpi
faecal
sampl
collect
evalu
consist
determin
oocyst
number
per
gram
opg
faec
diarrhoea
observ
calv
within
first
week
neither
prophylact
therapeut
use
ntz
improv
clinic
appear
calv
therapeut
show
longer
diarrheic
episod
p
strong
alter
faecal
consist
compar
untreat
control
group
number
day
oocyst
excret
differ
significantli
group
infect
treat
calv
oocyst
excret
stop
discontinu
treatment
prophylact
control
group
mean
valu
sum
daili
opg
per
calf
respect
mean
daili
number
opg
respect
similar
therapeut
group
show
significantli
lower
valu
respect
p
howev
oocyst
determin
group
may
alter
sever
diarrhoea
dilut
oocyst
densiti
analys
faecal
sampl
conclus
preliminari
result
first
prophylact
therapeut
use
ntz
calv
show
expect
posit
effect
cours
cryptosporidiuminfect
neither
reduc
clinic
sever
oocyst
excret
elsevi
bv
right
reserv
olson
et
al
bovin
cryptosporidiosi
occur
worldwid
preval
young
calv
differ
european
countri
appelbe
et
al
studi
perform
unit
state
show
particularli
calv
week
age
excret
c
parvum
oocyst
santin
et
al
preval
calv
week
age
preval
milk
cow
significantli
lower
mainli
concern
c
parvum
repres
zoonot
speci
also
pathogen
speci
cattl
fayer
et
al
although
c
parvum
infect
often
detect
combin
enteropathogen
rotaviru
coronaviru
escherichia
coli
salmonella
speci
mani
experiment
studi
investig
field
shown
cryptosporidium
may
act
primari
pathogen
tzipori
et
al
naciri
et
al
substanc
test
cryptosporidiosi
odonoghu
stockdal
et
al
halofuginon
decoquin
report
exhibit
promis
effect
lefay
et
al
lallemand
et
al
prophylact
administr
paromomycin
inhibit
oocyst
shed
reduc
number
day
diarrhoea
experiment
infect
calv
fayer
elli
field
trial
oocyst
shed
diarrhoea
start
withdraw
drug
reduct
diseas
obtain
grinberg
et
al
report
outcom
halofuginon
treatment
controversi
studi
calv
show
significantli
reduc
oocyst
excret
decreas
diarrhoea
joachim
et
al
prevent
mortal
naciri
et
al
anoth
studi
treatment
halofuginon
decoquin
effect
level
diarrhoea
dehydr
halofuginon
significantli
reduc
excret
oocyst
decoquin
increas
averag
daili
weight
gain
calv
lallemand
et
al
studi
administr
halofuginon
first
day
life
inhibit
oocyst
excret
week
age
incid
diarrhoea
delay
day
signific
differ
compar
control
group
concern
weight
gain
jarvi
et
al
halofuginon
drug
current
avail
treatment
bovin
cryptosporidiosi
known
rel
toxic
care
must
taken
exceed
therapeut
dose
nitazoxanid
ntz
antimicrobi
substanc
appli
antiparasit
treatment
dog
cat
sheep
goat
euzebi
et
al
gookin
et
al
viel
et
al
ntz
fdaapprov
human
use
treatment
cryptosporidiosi
giardiasi
children
adult
also
treatment
equin
protozoan
myeloenceph
caus
sarcocysti
neurona
goal
present
pilot
studi
investig
efficaci
ntz
prophylaxi
treatment
cryptosporidiosi
calv
anim
experi
approv
supervis
canton
veterinari
offic
rich
respect
anim
experiment
ethic
committe
studi
carri
maydecemb
experiment
barn
part
veterinari
hospit
univers
zurich
switzerland
calv
purchas
surround
farm
day
birth
calv
receiv
colostrum
hous
pen
group
anim
litter
straw
concret
base
pen
clean
daili
hot
vapour
pressur
calv
fed
commerci
milk
replac
suppli
automat
milk
deliver
anim
reduc
appetit
addit
handf
milk
andor
electrolyt
solut
water
suppli
ad
libitum
third
week
hay
also
avail
calv
neither
vaccin
receiv
supplementari
vitamin
experi
anim
check
twice
daili
clinic
includ
faecal
consist
appetit
weight
record
daili
first
manifest
diarrhoea
faec
calv
test
antigen
bovin
coronaviru
fastest
bcv
rotaviru
fastest
rota
e
coli
main
pilar
fastest
e
c
parvum
fastest
crypto
megacor
austria
calv
euthan
dpi
part
postmortem
analysi
addit
examin
antigen
detect
skin
biopsi
hilb
et
al
presenc
bovin
viru
diarrhoea
bvd
exclud
persist
primari
postnat
infect
bvd
viru
result
immunosuppress
therebi
enhanc
vulner
calv
secondari
infect
potgiet
cryptosporidiumisol
use
studi
origin
affect
outpati
calf
anim
hospit
oocyst
product
achiev
experiment
inocul
calf
oocyst
faec
calf
collect
mean
bag
attach
applianc
around
belli
anim
oocyst
purifi
ficol
gradient
c
parvum
cattl
genotyp
identifi
ward
et
al
oocyst
store
maximum
day
phosphat
buffer
salin
use
infect
experi
first
ntz
fed
three
calv
repres
uninfect
treatment
group
period
day
start
day
arriv
experiment
farm
determin
ntz
metabolit
afterward
upon
arriv
experiment
barn
calv
randomli
assign
three
experiment
group
day
anim
inocul
c
parvum
oocyst
first
group
prophylact
group
ntz
administ
prior
inocul
day
daili
period
day
ntz
kindli
provid
cambrex
profarmaco
landen
nv
belgium
fed
suckl
bottl
milk
replac
mgkg
bodyweight
bw
twice
daili
three
calv
second
group
therapeut
group
receiv
ntz
start
time
point
first
manifest
diarrhoea
daili
period
day
three
calv
third
group
infect
control
group
left
untreat
blood
sampl
taken
prior
drug
treatment
h
first
administr
ntz
calv
uninfect
treatment
group
sampl
sent
sg
life
scienc
servic
wavr
belgium
determin
activ
metabolit
tizoxanid
tizoxanid
glucuronid
previous
describ
stettler
et
al
faecal
sampl
directli
collect
contain
dl
rectum
calv
everi
day
sampl
label
seal
transport
laboratori
day
collect
singl
faecal
smear
prepar
mix
sampl
stain
ziehlneelsen
eckert
et
al
visualis
oocyst
entir
examin
microscopi
oocyst
present
sampl
analys
modifi
method
grinberg
et
al
determin
number
cryptosporidi
oocyst
per
gram
opg
faec
briefli
g
mix
faecal
sampl
mix
ml
tap
water
pass
siev
suspens
centrifug
sediment
resuspend
ml
normal
salin
afterward
ml
suspens
pour
drop
slide
airdri
stain
ziehlneelsen
entir
area
smear
examin
object
len
oocyst
count
opg
calcul
multipli
result
mani
oocyst
count
sampl
previous
dilut
result
correct
dilut
diarrhoeic
stool
mean
opg
calf
arithmet
mean
daili
opg
day
dpi
number
oocyst
shed
sum
daili
opg
calf
determin
effect
total
number
oocyst
shed
would
requir
collect
faec
day
possibl
faecal
consist
base
score
faec
solid
brownish
adhes
plastic
contain
faec
semisolid
yellowish
without
adhes
plastic
contain
sampl
spread
across
bottom
contain
liquid
liquid
diarrhoea
previous
describ
grinberg
et
al
differ
oocyst
excret
intens
statist
compar
maximum
likelihood
estim
base
neg
binomi
distribut
torgerson
et
al
consid
signific
valu
p
number
day
diarrhoea
semisolid
faecal
consist
compar
treatment
control
group
use
student
ttest
blood
sampl
uninfect
ntz
treat
calv
contain
ntz
metabolit
fig
tizoxanid
tiz
repres
deacetyl
primari
metabolit
first
detect
within
h
administr
limit
traceabl
mgml
highest
tizlevel
record
h
mgml
follow
decreas
next
administr
tizoxanid
glucuronid
tig
first
detect
slightli
tiz
limit
traceabl
mgml
highest
level
also
seen
h
mgml
tig
longer
detect
h
oral
administr
human
maximum
plasma
concentr
metabolit
also
observ
within
h
reach
level
mgml
broekhuysen
et
al
oral
administr
milk
milk
replac
h
interv
seem
appropri
way
ntz
administr
cryptosporidiuminfect
took
place
infect
anim
none
calv
includ
uninfect
ntz
treat
anim
posit
viral
bacteri
agent
test
c
parvum
rotaand
coronavirus
e
coli
infecti
agent
potenti
caus
diarrhoea
could
exclud
skin
biopsi
postmortem
neg
bvd
viru
alter
faecal
consist
particularli
diarrhoea
main
symptom
cryptosporidiosi
calv
observ
anim
differ
durat
sever
tabl
therapeut
group
anim
show
significantli
higher
p
number
day
liquid
diarrhoea
compar
infect
untreat
control
group
bloodi
faec
present
day
prophylact
therapeut
group
respect
infect
untreat
control
group
mean
day
bloodi
faec
differ
signific
also
calv
uninfect
group
receiv
ntz
develop
diarrhoea
mean
durat
day
blood
present
faec
one
calf
day
treatment
second
calf
day
third
calf
day
mean
day
per
anim
thu
diarrhoea
uninfect
group
possibl
caus
ntz
treatment
untreat
control
group
conspicu
liquid
diarrhoea
detect
day
day
alter
faecal
consist
indic
less
patholog
compar
treatment
group
percentag
uninfect
prophylact
therapeut
group
twice
much
respect
addit
day
respect
day
day
liquid
diarrhoea
prophylact
therapeut
group
occur
ntz
administr
suggest
cumul
neg
effect
ntz
combin
parasit
infect
result
daili
opg
determin
infect
calv
present
tabl
dynam
oocyst
excret
shown
fig
oocyst
excret
start
infect
anim
within
dpi
day
postinocul
highest
excret
oocyst
took
place
dpi
infect
treatment
group
faecal
consist
chang
start
oocyst
excret
discontinu
medic
prophylact
therapeut
group
mean
durat
oocyst
excret
day
respect
consequ
calv
two
group
excret
oocyst
mainli
treatment
day
respect
number
oocyst
shed
daili
mean
opg
valu
significantli
lower
therapeut
group
howev
oocyst
count
group
may
alter
sever
diarrhoea
dilut
oocyst
densiti
faecal
sampl
one
chronic
carrier
note
prophylact
control
group
none
therapeut
group
howev
number
excret
oocyst
dpi
chronic
carrier
low
also
faecal
consist
two
anim
alter
dpi
dpi
calv
longer
excret
oocyst
except
one
anim
excret
dpi
nevertheless
anim
continu
alter
faecal
consist
sever
day
hors
treat
neurona
infect
receiv
mg
kg
bw
day
mgkg
bw
day
day
see
us
food
drug
administr
navig
idexx
laboratori
previou
experi
anim
mice
rat
pig
cat
treat
higher
dosag
ntz
mgkg
bw
day
blagburn
et
al
mgkg
bw
day
li
et
al
mgkg
day
theodo
et
al
mgkg
bw
day
gookin
et
al
euzebi
et
al
describ
use
ntz
adult
dog
cat
sheep
dosag
mgkg
bw
observ
gener
toler
excel
howev
speci
soften
faecal
consist
almost
subdiarrho
pattern
appear
h
administr
ntz
mild
diarrhoea
last
approxim
h
enter
lesion
observ
postmortem
analysi
except
mild
catarrh
inflamm
sheep
oral
administr
ntz
dosag
mgkg
bw
bid
calv
studi
twice
usual
dosag
tabl
diarrhoea
calv
experiment
infect
cryptosporidium
oocyst
p
tand
cgroup
andor
treat
nitazoxanid
first
day
experi
uninfect
ntz
pand
tgroup
human
patient
protozoan
infect
mgkg
bw
everi
h
consecut
day
recommend
romero
cabello
et
al
seem
appropri
dosag
preliminari
studi
clinic
studi
paediatr
patient
alinia
nitazoxanid
wwwmosbysdrugconsultcomdrugconsult
frequent
advers
event
report
regardless
causal
assess
abdomin
pain
diarrhoea
follow
vomit
headach
nevertheless
symptom
children
mild
transient
differ
significantli
placebogroup
initi
studi
group
design
consist
anim
howev
experi
termin
group
anim
sinc
preliminari
result
show
expect
posit
effect
cours
cryptosporidiuminfect
contrari
data
uninfect
treat
group
suggest
ntz
direct
neg
effect
mucou
membran
gastrointestin
tract
calv
problem
also
seen
piglet
theodo
et
al
cat
gookin
et
al
result
support
viel
et
al
report
use
ntz
navig
equin
past
idexx
laboratori
kid
experiment
infect
c
parvum
acut
toxic
similar
result
concern
oocyst
excret
clinic
outcom
observ
experi
total
anim
drug
describ
also
activ
microaerophil
anaerob
bacteria
gastrointestin
flora
euzebi
et
al
could
therefor
caus
signific
problem
gastrointestin
tract
rumin
turn
could
seriou
diseas
fox
saravolatz
hemphil
et
al
specul
gastrointestin
problem
could
due
action
enzym
pyruv
ferredoxin
oxidoreductas
pfor
nitroreductas
hypothes
reduc
thiazol
ringassoci
nitro
group
thu
kill
intestin
bacteri
flora
product
free
radic
sisson
et
al
hoffman
et
al
review
hemphil
et
al
concomit
c
parvuminfect
infecti
agent
damag
superfici
intestin
epithelium
may
enhanc
potenti
toxic
treatment
substanc
due
augment
resorpt
consequ
sever
diarrhoea
may
increas
augment
also
dehydr
mortal
anim
particularli
delic
age
group
first
report
use
ntz
cryptosporidiosi
calv
conclus
neither
prophylact
therapeut
use
ntz
new
born
calv
infect
c
parvum
improv
clinic
appear
preliminari
experi
diminish
intens
durat
oocyst
excret
treatment
ntz
show
expect
anticryptosporidi
effect
appear
fail
histopatholog
would
requir
support
hypothesi
ntz
neg
impact
integr
intestin
epithelium
normal
flora
calv
consider
anim
welfar
reason
result
studi
suffici
encourag
justifi
prosecut
experi
tabl
number
day
oocyst
excret
mean
opg
base
daili
faecal
sampl
dpi
number
oocyst
shed
sum
daili
opg
per
calf
day
postinfect
calf
prophylact
therapeut
control
group
number
day
oocyst
excret
mean
opg
excret
number
oocyst
shed
prophylact
group
mean
sd
therapeut
group
mean
sd
control
group
mean
sd
chronic
carrier
b
p
maximum
likelihood
estim
base
neg
binomi
distribut
statist
studi
conduct
accord
ethic
guidelin
approv
ethic
committe
canton
veterinari
offic
canton
rich
permiss
number
